カテゴリ： GlobalData, イギリス, 企業調査

AstraZeneca Plc (AZN)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：AstraZeneca Plc (AZN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7237
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：141
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. It is also developing new approaches to the treatment of asthma. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc (AZN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
AstraZeneca Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
AstraZeneca Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
AstraZeneca Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
AstraZeneca Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
AstraZeneca Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
AstraZeneca Plc, Medical Equipment, Deal Details 15
Venture Financing 15
Rani Therapeutics Raises Funds in Financing 15
Definiens Raises USD20.3 Million in Venture Financing Round 17
CeraPedics Raises US$19 Million In Series C Financing 18
Definiens Raises US$13 Million In Venture Financing 19
Partnerships 20
AstraZeneca Enters into Licensing Agreement with Pelago Bioscience 20
AstraZeneca Enters into Agreement with Genedata 21
Definiens Enters into Co-Development Agreement with Merck 22
Emulate Enters into Partnership Agreement with AstraZeneca 23
Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 24
Chembio Diagnostic Enters into Agreement with AstraZeneca 25
Trovagene Enters into Agreement with AstraZeneca 26
AstraZeneca Enters into Partnership with DNAnexus 27
NeoGenomics and Definiens Enter into Agreement 28
SenzaGen Enters into Agreement with AstraZeneca 29
Guardant Health Enters into Agreement with AstraZeneca, Merck and Pfizer 30
AgPlus Diagnostics Enters into Agreement with AstraZeneca 31
Indivumed Partners with Definiens 32
Foundation Medicine Enters into Agreement with AstraZeneca 33
Definiens Partners with MolecularMD 34
MedImmune Enters into Agreement with Genisphere 35
Human Longevity Partners with AstraZeneca 36
PROOF Centre Partners with AstraZeneca 37
Cepheid, MedImmune and Combacte Enter into Agreement 38
Labcyte Enters into Agreement with AstraZeneca 39
HighRes Biosolutions Enters into Agreement with AstraZeneca 40
AstraZeneca Enters into Research Agreement with Sutter Health 41
Myriad Genetics Expands Agreement with AstraZeneca 42
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 43
AstraZeneca Enters into Co-Development Agreement with Qiagen 44
AstraZeneca Enters into Co-Development Agreement with Roche 45
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 46
Ventana Medical Enters into Co-Development Agreement with MedImmune 47
Definiens Enters Into Agreement With Metamark For ProMark Prognostic Test 48
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 49
Oxford Cancer Biomarkers Enters Into Agreement With AstraZeneca For Biomarker Discovery 50
AstraZeneca Enters Into Research Agreement With Karolinska Institutet 51
Merger 52
AstraZeneca Rumored To Merge With Amgen 52
Equity Offering 53
OnDosis Spins Out from AstraZeneca 53
Debt Offering 54
AstraZeneca Prices Public Offering of 3.5% Notes due 2023 for USD0.85 Billion 54
AstraZeneca Prices Public Offering of 4% Notes due 2029 for USD1 Billion 56
AstraZeneca Prices Public Offering of 4.375% Notes due 2048 for USD0.75 Billion 58
AstraZeneca Prices Public Offering of Floating Rate Notes due 2023 for USD0.4 Billion 60
AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 62
Acquisition 63
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 63
Pfizer May Increase Bid to Acquire AstraZeneca 64
MedImmune Acquires Definiens for USD150 Million 66
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 67
AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 69
AstraZeneca Plc – Key Competitors 70
AstraZeneca Plc – Key Employees 71
AstraZeneca Plc – Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Joint Venture 80
Recent Developments 81
Strategy And Business Planning 81
Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZeneca’s BioVentureHub 81
Apr 25, 2017: AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK 82
Financial Announcements 84
Jul 26, 2018: AstraZeneca announces H1 2018 results 84
May 18, 2018: AstraZeneca: Q1 2018 Results 98
Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 100
Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 102
Jul 27, 2017: AstraZeneca Announce H1 2017 Results 110
Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 120
Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 121
Corporate Communications 122
Sep 06, 2018: AstraZeneca: Directorate change 122
Jun 26, 2018: AstraZeneca Announces Board Committee Changes 123
Apr 05, 2018: AstraZeneca: Non-Executive Directors’ Retirement Plans 124
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 125
Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 126
Aug 16, 2017: Astrazeneca Non-executive Director Retirement 128
Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 129
Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 130
May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 131
Mar 06, 2017: Changes to AstraZeneca Board of Directors 132
Legal and Regulatory 133
Aug 01, 2018: AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists 133
Product News 134
Jul 09, 2018: Microsoft and Partners Showcase a New ‘Molecule’ for Better Health Outcomes 134
Other Significant Developments 135
Jul 10, 2018: Revon Systems’ Digital Therapeutics Enters Collaboration with AstraZeneca in Respiratory Medicine 135
Jan 25, 2018: ACT Genomics collaborates with AstraZeneca on BRCA testing 136
Nov 01, 2017: CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies 137
Sep 27, 2017: Inhalation Sciences gets large order from AstraZeneca 138
Jun 06, 2017: AstraZeneca Selects ArisGlobal LifeSphere Safety – Risk Management 139
Mar 31, 2017: First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal 140
Appendix 141
Methodology 141
About GlobalData 141
Contact Us 141
Disclaimer 141

List of Tables
AstraZeneca Plc, Medical Equipment, Key Facts, 2017 2
AstraZeneca Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
AstraZeneca Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
AstraZeneca Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 9
AstraZeneca Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
AstraZeneca Plc, Deals By Market, 2012 to YTD 2018 11
AstraZeneca Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Rani Therapeutics Raises Funds in Financing 15
Definiens Raises USD20.3 Million in Venture Financing Round 17
CeraPedics Raises US$19 Million In Series C Financing 18
Definiens Raises US$13 Million In Venture Financing 19
AstraZeneca Enters into Licensing Agreement with Pelago Bioscience 20
AstraZeneca Enters into Agreement with Genedata 21
Definiens Enters into Co-Development Agreement with Merck 22
Emulate Enters into Partnership Agreement with AstraZeneca 23
Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 24
Chembio Diagnostic Enters into Agreement with AstraZeneca 25
Trovagene Enters into Agreement with AstraZeneca 26
AstraZeneca Enters into Partnership with DNAnexus 27
NeoGenomics and Definiens Enter into Agreement 28
SenzaGen Enters into Agreement with AstraZeneca 29
Guardant Health Enters into Agreement with AstraZeneca, Merck and Pfizer 30
AgPlus Diagnostics Enters into Agreement with AstraZeneca 31
Indivumed Partners with Definiens 32
Foundation Medicine Enters into Agreement with AstraZeneca 33
Definiens Partners with MolecularMD 34
MedImmune Enters into Agreement with Genisphere 35
Human Longevity Partners with AstraZeneca 36
PROOF Centre Partners with AstraZeneca 37
Cepheid, MedImmune and Combacte Enter into Agreement 38
Labcyte Enters into Agreement with AstraZeneca 39
HighRes Biosolutions Enters into Agreement with AstraZeneca 40
AstraZeneca Enters into Research Agreement with Sutter Health 41
Myriad Genetics Expands Agreement with AstraZeneca 42
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 43
AstraZeneca Enters into Co-Development Agreement with Qiagen 44
AstraZeneca Enters into Co-Development Agreement with Roche 45
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 46
Ventana Medical Enters into Co-Development Agreement with MedImmune 47
Definiens Enters Into Agreement With Metamark For ProMark Prognostic Test 48
Myriad Genetics Expands Agreement with AstraZeneca for Olaparib 49
Oxford Cancer Biomarkers Enters Into Agreement With AstraZeneca For Biomarker Discovery 50
AstraZeneca Enters Into Research Agreement With Karolinska Institutet 51
AstraZeneca Rumored To Merge With Amgen 52
OnDosis Spins Out from AstraZeneca 53
AstraZeneca Prices Public Offering of 3.5% Notes due 2023 for USD0.85 Billion 54
AstraZeneca Prices Public Offering of 4% Notes due 2029 for USD1 Billion 56
AstraZeneca Prices Public Offering of 4.375% Notes due 2048 for USD0.75 Billion 58
AstraZeneca Prices Public Offering of Floating Rate Notes due 2023 for USD0.4 Billion 60
AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 62
AstraZeneca to Acquire Additional 5.7% Stake in Circassia Pharma 63
Pfizer May Increase Bid to Acquire AstraZeneca 64
MedImmune Acquires Definiens for USD150 Million 66
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 67
AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 69
AstraZeneca Plc, Key Competitors 70
AstraZeneca Plc, Key Employees 71
AstraZeneca Plc, Subsidiaries 74
AstraZeneca Plc, Joint Venture 80

List of Figures
AstraZeneca Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
AstraZeneca Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
AstraZeneca Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
AstraZeneca Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
AstraZeneca Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
AstraZeneca Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
AstraZeneca Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
AstraZeneca Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

★海外企業調査レポート[AstraZeneca Plc (AZN)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Yeo Hiap Seng Limited：企業の戦略・SWOT・財務情報
    Yeo Hiap Seng Limited - Strategy, SWOT and Corporate Finance Report Summary Yeo Hiap Seng Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • EOH Holdings Ltd (EOH)：企業の財務・戦略的SWOT分析
    EOH Holdings Ltd (EOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Loblaw Companies Limited：戦略・SWOT・企業財務分析
    Loblaw Companies Limited - Strategy, SWOT and Corporate Finance Report Summary Loblaw Companies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • PT Bank CIMB Niaga Tbk (BNGA)：企業の財務・戦略的SWOT分析
    PT Bank CIMB Niaga Tbk (BNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Rizal Commercial Banking Corp (RCB)：企業の財務・戦略的SWOT分析
    Summary Rizal Commercial Banking Corp (RCBC) is a commercial and financial banking service provider that offers corporate, commercial, and consumer banking, cash management, treasury, and remittance products and services. The company’s electronic banking services include mobile banking, internet ban …
  • Swiss Life Holding Ltd：企業の戦略・SWOT・財務情報
    Swiss Life Holding Ltd - Strategy, SWOT and Corporate Finance Report Summary Swiss Life Holding Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • San Miguel Corp：企業の戦略・SWOT・財務情報
    San Miguel Corp - Strategy, SWOT and Corporate Finance Report Summary San Miguel Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hologic Inc (HOLX)-製薬・医療分野：企業M&A・提携分析
    Summary Hologic Inc (Hologic) is a medical device company. It develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products. The company offers diagnostic products to aid in the diagnosis of human diseases and screen donated human blood; a broad portfolio of …
  • University of California Berkeley：製薬・医療：M&Aディール及び事業提携情報
    Summary University of California Berkeley (UC Berkeley), a subsidiary of University of California is an educational university that offers educational programs and research services. The university’s academic programs comprise law and economics program, legal studies; lesbian, gay, bisexual, and tra …
  • Brady Corporation (BRC)：企業の財務・戦略的SWOT分析
    Brady Corporation (BRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hamilton Thorne Ltd (HTL)：企業の財務・戦略的SWOT分析
    Summary Hamilton Thorne Ltd (Hamilton Thorne) is a medical equipment company that offers precision laser devices and advanced image analysis systems. The company's products include clinical lasers, animal and research sperm analysis products, research lasers, clinical sperm analysis products, sperm …
  • Merck KGaA (MRK)：医療機器：M&Aディール及び事業提携情報
    Summary Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, O …
  • Bilim Pharmaceuticals：企業の戦略的SWOT分析
    Bilim Pharmaceuticals - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • SURFnet bv：企業の戦略的SWOT分析
    SURFnet bv - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Xcel Energy Inc (XEL)-エネルギー分野：企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Midatech Pharma US Inc：医療機器：M&Aディール及び事業提携情報
    Summary Midatech Pharma US Inc (Midatech Pharma), formerly DARA BioSciences, Inc., is a pharmaceutical company which focuses on the development and commercialization of cancer treatment and supportive care products. It is a subsidiary of Midatech Pharma Plc. The company’s product portfolio includes …
  • Abivax SA (ABVX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce f …
  • MAXIMUS Inc (MMS)：企業の財務・戦略的SWOT分析
    MAXIMUS Inc (MMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Artizian Catering Services Ltd：企業の戦略・SWOT・財務分析
    Artizian Catering Services Ltd - Strategy, SWOT and Corporate Finance Report Summary Artizian Catering Services Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Channel Four Telivision Corp：企業の戦略的SWOT分析
    Channel Four Telivision Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆